Moore KT - Search Results

1

Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease.

Weir MR, Ashton V, Moore KT, Shrivastava S, Peterson ED, Ammann EM. Weir MR, et al. Among authors: moore kt. Am Heart J. 2020 May;223:3-11. doi: 10.1016/j.ahj.2020.01.010. Epub 2020 Jan 22. Am Heart J. 2020. PMID: 32112872 Free article.

2

Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF.

Girgis IG, Patel MR, Peters GR, Moore KT, Mahaffey KW, Nessel CC, Halperin JL, Califf RM, Fox KA, Becker RC. Girgis IG, et al. Among authors: moore kt. J Clin Pharmacol. 2014 Aug;54(8):917-27. doi: 10.1002/jcph.288. Epub 2014 Mar 26. J Clin Pharmacol. 2014. PMID: 24668660 Free article. Clinical Trial.

3

Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis.

Dias C, Moore KT, Murphy J, Ariyawansa J, Smith W, Mills RM, Weir MR. Dias C, et al. Among authors: moore kt. Am J Nephrol. 2016;43(4):229-36. doi: 10.1159/000445328. Epub 2016 Apr 22. Am J Nephrol. 2016. PMID: 27100875 Free article.

4

Rivaroxaban in Chronic Hemodialysis Patients: Clarification of an Editorial Error.

Dias C, Moore KT, Murphy J, Ariyawansa J, Smith W, Mills RM, Weir MR. Dias C, et al. Among authors: moore kt. Am J Nephrol. 2016;44(2):169. doi: 10.1159/000448817. Epub 2016 Aug 23. Am J Nephrol. 2016. PMID: 27548702 Free article. No abstract available.

5

Influence of age on the pharmacokinetics, pharmacodynamics, efficacy, and safety of rivaroxaban.

Moore KT, Wong P, Zhang L, Pan G, Foody J. Moore KT, et al. Curr Med Res Opin. 2018 Dec;34(12):2053-2061. doi: 10.1080/03007995.2018.1492374. Epub 2018 Aug 5. Curr Med Res Opin. 2018. PMID: 29932775 Review.

6

Clarification of the use of rivaroxaban in renal patients.

Moore KT. Moore KT. Br J Haematol. 2019 Apr;185(2):381-382. doi: 10.1111/bjh.15523. Epub 2018 Jul 24. Br J Haematol. 2019. PMID: 30043498 Free article. No abstract available.

7

The Use of Rivaroxaban in Patients With Atrial Fibrillation Receiving Hemodialysis-Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.

Moore KT. Moore KT. Chest. 2019 Jun;155(6):1306-1307. doi: 10.1016/j.chest.2019.02.323. Chest. 2019. PMID: 31174647 No abstract available.

8

Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data.

Costa OS, Beyer-Westendorf J, Ashton V, Milentijevic D, Moore KT, Bunz TJ, Coleman CI. Costa OS, et al. Among authors: moore kt. Curr Med Res Opin. 2020 Jul;36(7):1081-1088. doi: 10.1080/03007995.2020.1762554. Epub 2020 May 13. Curr Med Res Opin. 2020. PMID: 32347755 Free article.

9

Response to letter regarding article "Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease".

Weir MR, Ashton V, Moore KT, Shrivastava S, Peterson ED, Ammann EM. Weir MR, et al. Among authors: moore kt. Am Heart J. 2020 May;223:111-112. doi: 10.1016/j.ahj.2020.03.002. Epub 2020 Mar 7. Am Heart J. 2020. PMID: 32386598 No abstract available.

10

Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data.

Costa OS, Beyer-Westendorf J, Ashton V, Milentijevic D, Moore KT, Bunz TJ, Coleman CI. Costa OS, et al. Among authors: moore kt. J Thromb Thrombolysis. 2021 Feb;51(2):349-358. doi: 10.1007/s11239-020-02199-0. J Thromb Thrombolysis. 2021. PMID: 32588288

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

86 results

Search Page

Filters